The application of AI in science and medicine took a massive leap forward. Google DeepMind unveiled AlphaGenome, a tool designed to analyze vast stretches of DNA to predict how genetic variants influence disease and gene regulation, a breakthrough that promises to accelerate genomic medicine . Simultaneously, researchers at Stanford Medicine introduced SleepFM, an AI model that can analyze data from a single night’s sleep to predict the risk of developing over 100 conditions, including dementia and heart disease, by detecting subtle interactions in biological signals that human clinicians miss.

In the commercial healthcare sector, OpenAI launched ChatGPT Health, a specialized tier designed to help users navigate medical questions with enhanced privacy safeguards and clinician-informed responses . This was part of a broader commercial push that included a partnership with ServiceNow to embed GPT-5.2 into over 80 billion enterprise workflows, effectively making it the “preferred intelligence capability” for automating IT, HR, and finance tasks . However, the company also signaled a shift in its consumer strategy by announcing it would begin testing ads on its free and low-tier ChatGPT services, a move aimed at monetizing its massive user base without raising subscription prices.